Drugs / Bulumtatug Fuvedotin
Bulumtatug Fuvedotin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06908928 | Aug 2025 → May 2027 expected | triple-negative breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05216965 | Jun 2022 → Dec 2025 | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06692166 | Sep 2024 → Dec 2027 expected | cervical cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06196736 | Dec 2023 → Sep 2026 expected | urothelial carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bulumtatug fuvedotin | “BACKGROUND: A first-in-human study was carried out to assess the safety and preliminary antitumor activity of bulumtatug fuvedotin (BFv; 9MW2821), a next-generation monoclonal...” PMID 40288679 ↗ Apr 2025 |
| Known as | 9MW2821 | “BACKGROUND: A first-in-human study was carried out to assess the safety and preliminary antitumor activity of bulumtatug fuvedotin (BFv; 9MW2821), a next-generation monoclonal...” PMID 40288679 ↗ Apr 20251“An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects With Recurrent or Metastatic Triple-Negative Breast Cancer...” NCT06908928 ↗ |
| Known as | BFv | “BACKGROUND: A first-in-human study was carried out to assess the safety and preliminary antitumor activity of bulumtatug fuvedotin (BFv; 9MW2821), a next-generation monoclonal...” PMID 40288679 ↗ Apr 20251“An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects With Recurrent or Metastatic Triple-Negative Breast Cancer...” NCT06908928 ↗ |
| Modality | Monoclonal antibody | “a next-generation monoclonal antibody-drug conjugate (ADC)” PMID 40288679 ↗ Apr 2025 |
| Route | Intravenous | “receive BFv by intravenous (IV) infusion” PMID 40288679 ↗ Apr 2025 |